SCHEMBL4676607

SCHEMBL4676607

O=C(C=C(O)c1nc[nH]n1)c1ccoc1Cc1ccccc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
ATM Q13315 1/20 0.32
NLRP3 Q96P20 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4A O75164 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
P2RX7 Q99572 1/20 0.32
CFTR P13569 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
TP53 P04637 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675787 0.88 ALDH1A1 (0.37) ALDH1A1KDM5BTP53BRS3
SCHEMBL4677650 0.86 TP53 (0.35) ALDH1A1POLBKDM4AKDM4CKDM5B
SCHEMBL4675705 0.86 NPC1 (0.41) LMNATDP1ALDH1A1POLBSMN1; SMN2
SCHEMBL4671783 0.85 NLRP3 (0.35) LMNATDP1PDE3BPDE3AALDH1A1
SCHEMBL4674056 0.85 GPR52 (0.35) TDP1ALDH1A1ATMSMN1; SMN2
SCHEMBL4675254 0.83 KDM4C (0.34) LMNAKDM4AKDM4CKDM5BL3MBTL1
SCHEMBL4679843 0.83 SMN1; SMN2 (0.41) LMNAPDE3BPDE3AALDH1A1SMN1; SMN2
SCHEMBL4673098 0.82 L3MBTL1 (0.39) LMNATDP1ALDH1A1POLBSMN1; SMN2
SCHEMBL4675027 0.82 AR (0.33) LMNATDP1PDE3BPDE3AALDH1A1
SCHEMBL4671571 0.80 TP53 (0.44) LMNAPOLBSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LMNA 659/4885TDP1 306/4885PDE3B 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.